CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 6978 result(s)

fremanezumab (Ajovy)

Last Updated: September 28, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: fremanezumab
Indications: migraine

  • Brand Name: Ajovy
  • Manufacturer: Teva Canada Innovation
  • Project Number: SR0641-000
  • Project Status: Active
  • Submission Type: New

dapagliflozin (Forxiga )

Last Updated: September 28, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: dapagliflozin
Indications: Heart failure with reduced ejection fraction

  • Brand Name: Forxiga
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0642-000
  • Project Status: Active
  • Submission Type: New

onasemnogene abeparvovec (Zolgensma)

Last Updated: September 28, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: onasemnogene abeparvovec
Indications: Spinal muscular atrophy (SMA), pediatrics

  • Brand Name: Zolgensma
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0649-000
  • Project Status: Active
  • Submission Type: New

etonogestrel (Nexplanon)

Last Updated: September 28, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: etonogestrel
Indications: Prevention of pregnancy

  • Brand Name: Nexplanon
  • Manufacturer: Merck Canada Inc.
  • Project Number: SR0648-000
  • Project Status: Active
  • Submission Type: New